STOK

$32.87

Post-MarketAs of Mar 17, 8:00 PM UTC

Stoke Therapeutics, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$32.87
Potential Downside
56.5%
Whystock Fair Value$14.28
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisen...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.88B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
48.34
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
15.02%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
6.21

Recent News

Simply Wall St.
Mar 12, 2026

Biogen Rare Disease Data And Valuation Discount Draw Investor Attention

Biogen (NasdaqGS:BIIB) reported one year results for salanersen in children with spinal muscular atrophy, showing clinical improvements and reduced neurodegeneration markers after once yearly dosing. The company outlined the initiation and design of a global Phase 3 program for salanersen in spinal muscular atrophy. Separately, Biogen and Stoke Therapeutics released data on zorevunersen indicating potential disease modification in Dravet syndrome. For investors watching NasdaqGS:BIIB, these...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 12, 2026

Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +168.87% and +3,813.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 11, 2026

Vertex (VRTX) Moves 8.3% Higher: Will This Strength Last?

Vertex (VRTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 6, 2026

How Investors May Respond To Stoke Therapeutics (STOK) NEJM Data And 2027 FDA Filing Timeline

In recent days, Stoke Therapeutics and Biogen reported that data on the investigational Dravet syndrome medicine zorevunersen were published in The New England Journal of Medicine, alongside Stoke’s updated Phase 3 EMPEROR timeline and plans to begin a rolling FDA New Drug Application submission in the first half of 2027. The publication underscored multi‑year reductions in seizures and cognitive and behavioral gains in Dravet patients, reinforcing the clinical thesis behind Stoke’s...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 5, 2026

Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar?

Dianthus Therapeutics, Inc. (DNTH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

BEARISH
Negative press. News cycle fixated on risk factors or misses.